CoChat

Clinical Recommendations to Manage Gastrointestinal Adverse Events in Patients Treated with Glp-1 Receptor Agonists: A Multidisciplinary Expert Consensus

Open access
Gorgojo-Martínez, Juan J., Mezquita-Raya, Pedro, Carretero-Gómez, Juana, Castro, Almudena, Cebrián-Cuenca, Ana, de Torres-Sánchez, Alejandra, García-de-Lucas, María Dolores, Núñez, Julio, Obaya, Juan Carlos, Soler, María José, Górriz, José Luis, Rubio-Herrera, Miguel Ángel · 2022 · Journal of Clinical Medicine

The DOI matches its Crossref record; 82 of the 83 references it cites were found in a registry or an index, and 1 are not checked yet.

Abstract

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are indicated in type 2 diabetes and obesity for their high efficacy in controlling glycaemia and inducing body weight loss, respectively. Patients may develop gastrointestinal adverse events (GI AEs), namely nausea, vomiting, diarrhoea and/or constipation. To minimize their severity and duration, healthcare providers (HCPs) and patients must be aware of appropriate measures to follow while undergoing treatment. An expert panel comprising endocrinologists, nephrologists, primary care physicians, cardiologists, internists and diabetes nurse educators convened across virtual meetings to reach a consensus regarding these compelling recommendations. Firstly, specific guidelines are provided about how to reach the maintenance dose and how to proceed if GI AEs develop during dose-escalation. Secondly, specific directions are set about how to avoid/minimize nausea, vomiting, diarrhoea and constipation symptoms. Clinical scenarios representing common situations in daily practice, and infographics useful to guide both HCPs and patients, are included. These recommendations may prevent people with T2D and/or obesity from withdrawing from GLP-1 RAs treatment, thus benefitting from their superior effect on glycaemic control and weight loss.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/jcm12010145

Cites

82 of 83 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Minimizing occurrence/severity of GI AEs: patients general guidelines.
Figure 1 Minimizing occurrence/severity of GI AEs: patients general guidelines.CC BY · PubMed Central
Figure 2 Additional specific guidelines for each separate GI AE.
Figure 2 Additional specific guidelines for each separate GI AE.CC BY · PubMed Central
Figure 3 Additional specific guidelines for unusually severe/persistent GI AEs.
Figure 3 Additional specific guidelines for unusually severe/persistent GI AEs.CC BY · PubMed Central
Figure 4 Minimizing occurrence/severity of GI AEs: the role of HCPs.
Figure 4 Minimizing occurrence/severity of GI AEs: the role of HCPs.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

10 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 2

  1. 2010, Liraglutide in the treatment of type 2 diabetes: Recommendations for better patients’ selection from a multidisciplinary approach, Av. Diabetol., 26, 226
  2. 2014, Pancreatitis aguda severa y precoz por liraglutide, Arch. Med. Int., 36, 119

Cited by

See all 358

Metadata

Authors
Gorgojo-Martínez, J. J., Mezquita-Raya, P., Carretero-Gómez, J., Castro, A., Cebrián-Cuenca, A., de Torres-Sánchez, A., García-de-Lucas, M. D., Núñez, J., Obaya, J. C., Soler, M. J., Górriz, J. L., & Rubio-Herrera, M. Á.
Affiliations
  • Department of Endocrinology and Nutrition, Hospital Universitario Fundación Alcorcón, 28922 Madrid, Spain
  • Department of Endocrinology and Nutrition, Hospital Universitario Torrecárdenas, 04009 Almería, Spain
  • Department of Internal Medicine, University Hospital of Badajoz, 06080 Badajoz, Spain
  • Hospital Universitario La Paz (ES)
  • Health Centre Casco Antiguo Cartagena, Primary Care Research Group, Biomedical Research Institute of Murcia (IMIB), 30201 Cartagena, Spain
  • Department of Internal Medicine, Costa del Sol Hospital, 29603 Marbella, Spain
  • Hospital Clínico Universitario de Valencia (ES)
  • Madrid Health Service (ES)
  • Vall d'Hebron Institut de Recerca (ES)
  • Universitat de València (ES)
  • Department of Endocrinology and Nutrition, San Carlos Clinical Hospital, Health Research Institute of the San Carlos Clinical Hospital (IDISSC), 28040 Madrid, Spain
Corresponding author
Górriz, José Luis
Venue
Journal of Clinical Medicine
Publisher
MDPI AG
Published
2022-12-24
Volume
12
Issue
1
Pages
145
ISSN
2077-0383 (ISSN-L)
OpenAlex
W4313260808
Cited by
358
References
83
Citations by year
2026: 137 · 2025: 140 · 2024: 63 · 2023: 18
FWCI
40.90
Type
journal article
Language
en
Open access
Locations
  • Journal of Clinical Medicine (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Repository of Digital Objects for Teaching Research and Culture (University of Valencia) (submittedVersion, other-oa)
Funders
Novo-Nordisk
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Keywords
GLP-1 receptor agonists, gastrointestinal adverse effects, nausea, vomiting, diarrhea, constipation, type 2 diabetes, obesity, dose escalation, maintenance dose, treatment discontinuation, glycemic control, weight loss, patient education

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.